[Anti-HER2 antibody and small-molecule tyrosine kinase inhibitor therapy targeting EGFR signal pathway].
The human epidermal growth factor receptor (HER) family plays a crucial role in progression of breast cancer. Anti-HER agents such as trastuzumab and lapatinib are known to exhibit significant antitumor activities in human HER2-positive breast cancers. At present, several novel anti-HER agents are being tested in clinical trials. These agents are estimated to be able to overcome resistance to previous anti-HER agents. Simultaneously, correlated research with these agents have contributed to improve our understanding of the molecular mechanism of HER-dependent breast cancer growth.